Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Truist Financial Corp

Truist Financial Corp reduced its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 18.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,801 shares of the company’s stock after selling 872 shares during the period. Truist Financial Corp’s holdings in Henry Schein were worth $244,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HSIC. Summit Securities Group LLC acquired a new stake in Henry Schein during the second quarter worth approximately $31,000. Beach Investment Counsel Inc. PA purchased a new stake in Henry Schein in the second quarter valued at $37,000. Blue Trust Inc. boosted its stake in Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after acquiring an additional 475 shares in the last quarter. Mather Group LLC. grew its holdings in shares of Henry Schein by 16.8% during the second quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock worth $96,000 after purchasing an additional 216 shares during the last quarter. Finally, Palisade Asset Management LLC acquired a new stake in shares of Henry Schein during the first quarter worth about $113,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Price Performance

Henry Schein stock opened at $72.39 on Friday. The firm has a market capitalization of $9.27 billion, a PE ratio of 24.46, a P/E/G ratio of 1.98 and a beta of 0.86. Henry Schein, Inc. has a 52 week low of $60.01 and a 52 week high of $82.63. The firm’s 50-day simple moving average is $70.40 and its 200 day simple moving average is $69.88. The company has a quick ratio of 0.90, a current ratio of 1.55 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. The firm had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. Henry Schein’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Activity at Henry Schein

In other news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.14% of the company’s stock.

Analysts Set New Price Targets

HSIC has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their target price on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Baird R W upgraded shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Robert W. Baird decreased their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Barrington Research reissued an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a report on Friday, September 20th. Finally, Evercore ISI upped their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. One analyst has rated the stock with a sell rating, six have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $77.50.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.